^
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
CRLF2 rearrangement
ALL
T-lymphocyte cell therapy + ruxolitinib
Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
CRLF2 rearrangement
ALL
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CD19 positive
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CRLF2 overexpression
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CRLF2 overexpression
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CRLF2 overexpression
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CD19 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
BeiGene Press Release - 3 weeks - (New A1)
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
imatinib
Sensitive: A1 - Approval
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
BCR-ABL1 T315I
ALL
ponatinib
Sensitive: A1 - Approval
No biomarker
ALL
blinatumomab
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
ponatinib
Sensitive: A1 - Approval
No biomarker
T Acute Lymphoblastic Leukemia
nelarabine
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
dasatinib
Sensitive: A1 - Approval
CD19 positive
ALL
blinatumomab
Sensitive: A1 - Approval
No biomarker
ALL
mercaptopurine
Sensitive: A1 - Approval
No biomarker
ALL
vincristine liposomal
Sensitive: A1 - Approval
No biomarker
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
brexucabtagene autoleucel
Sensitive: A1 - Approval
No biomarker
ALL
recombinant Erwinia asparaginase
Sensitive: A1 - Approval
No biomarker
ALL
pegaspargase
Sensitive: A1 - Approval
CD20 positive
Childhood B Acute Lymphoblastic Leukemia
rituximab
Sensitive: A1 - Approval
BCR-ABL1 V299L
ALL
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 F317I
ALL
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 T315I
ALL
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 fusion
ALL
nilotinib
Sensitive: A2 - Guideline
BCR-ABL1 T315I
ALL
bosutinib
Resistant: A2 - Guideline
BCR-ABL1 T315I
ALL
nilotinib
Resistant: A2 - Guideline
PDGFRA fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
ABL2 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
FGFR fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
IL7R mutation
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
SH2B3 alteration
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
CRLF2 rearrangement + JAK2 fusion
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
EPOR rearrangement
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
ALL
bosutinib
Sensitive: A2 - Guideline
BCR-ABL1 E255V
ALL
nilotinib
Resistant: A2 - Guideline
No biomarker
ALL
CALGB 10403
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
imatinib
Sensitive: A2 - Guideline
ABL1 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
JAK2 fusion
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: A2 - Guideline
No biomarker
ALL
prednisone + vincristine
Sensitive: A2 - Guideline
No biomarker
ALL
ifosfamide + etoposide oral + mitoxantrone
Sensitive: A2 - Guideline
No biomarker
ALL
cytarabine + methotrexate
Sensitive: A2 - Guideline
No biomarker
ALL
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
No biomarker
ALL
clofarabine
Sensitive: A2 - Guideline
PDGFRB fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
ALL
inotuzumab ozogamicin
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A2 - Guideline
No biomarker
T Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
vincristine + mitoxantrone + dexamethasone + pegaspargase
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + nelarabine
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
imatinib
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
No biomarker
Childhood B Acute Lymphoblastic Leukemia
bortezomib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
BCR-ABL1 G250E
ALL
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 fusion
ALL
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
No biomarker
ALL
inotuzumab ozogamicin
Sensitive: A2 - Guideline
No biomarker
ALL
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
ABL1 T315I
ALL
ponatinib
Sensitive: A2 - Guideline
BCR-ABL1 F317L
ALL
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 V299L
ALL
bosutinib
Resistant: A2 - Guideline
BCR-ABL1 F317L
ALL
nilotinib
Sensitive: A2 - Guideline
BCR-ABL1 F359I
ALL
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 F359C
ALL
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 F359V
ALL
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 E255K
ALL
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 Y253H
ALL
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 F317C
ALL
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 F317V
ALL
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 T315A
ALL
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 F317L
ALL
bosutinib
Resistant: A2 - Guideline
BCR-ABL1 G250E
ALL
bosutinib
Resistant: A2 - Guideline
CD20 positive
ALL
rituximab
Sensitive: A2 - Guideline
No biomarker
ALL
COG AALL0232
Sensitive: A2 - Guideline
No biomarker
ALL
MRC UKALLXII / ECOG2993
Sensitive: A2 - Guideline
No biomarker
ALL
Linker 4-drug
Sensitive: A2 - Guideline
No biomarker
ALL
CALGB 8811 Larson
Sensitive: A2 - Guideline
No biomarker
ALL
USC / MSKCC ALL
Sensitive: A2 - Guideline
No biomarker
ALL
PETHEMA ALL-96
Sensitive: A2 - Guideline
No biomarker
ALL
GRAALL-2005
Sensitive: A2 - Guideline
No biomarker
ALL
DFCI ALL
Sensitive: A2 - Guideline
No biomarker
ALL
COG AALL0434
Sensitive: A2 - Guideline
No biomarker
ALL
prednisone + vincristine + daunorubicin + pegaspargase
Sensitive: A2 - Guideline
No biomarker
T Acute Lymphoblastic Leukemia
prednisone + vincristine + daunorubicin + nelarabine + pegaspargase
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
bosutinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
nilotinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
ponatinib
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
vincristine liposomal
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
FLAG-IDA
Sensitive: A2 - Guideline
No biomarker
B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive: A2 - Guideline